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Influenza therapeutics with new targets and mechanisms of action are urgently needed to combat potential pandemics, emerging viruses, and constantly mutating strains in circulation. We report here on the design and structural characterization of potent peptidic inhibitors of influenza hemagglutinin. The peptide design was based on complementaritydetermining region loops of human broadly neutralizing antibodies against the hemagglutinin (FI6v3 and CR9114). The optimized peptides exhibit nanomolar affinity and neutralization against influenza A group 1 viruses, including the 2009 H1N1 pandemic and avian H5N1 strains. The peptide inhibitors bind to the highly conserved stem epitope and block the low pH-induced conformational rearrangements associated with membrane fusion. These peptidic compounds and their advantageous biological properties should accelerate the development of new small molecule-and peptide-based therapeutics against influenza virus.
T he influenza drug therapies that are currently available worldwide target only two viral proteins-the M2 channel and neuraminidase (NA)-both of which function at critical stages of the virus life cycle. M2 is involved in proton-conducting activity in the early and late stages of replication, and NA is involved in the release of nascent virions (1, 2) . However, escape mutations have resulted in drug-resistant viruses against which the therapeutic effects of these drugs are diminished or ablated (3, 4) . Therefore, therapeutics with different mechanisms of action are urgently required to combat the persistent global threat imposed by influenza virus. Therapeutic strategies aimed at targeting the highly conserved functional regions on influenza hemagglutinin (HA) that are involved in viral entry should be highly effective and may reduce the likelihood of generating escape mutants.
Infection by influenza virus is initiated by HA receptor binding at the cell surface and then by HA-mediated fusion of viral and host cellular membranes in the low pH of endosomal compartments (5). HA is the major glycoprotein on the influenza virus surface and is a homotrimer, with each monomer composed of two subunits, HA1 and HA2, linked by a single disulfide bond (6) . The HA1 subunit forms the membrane-distal globular head that contains the receptor binding site (RBS), as well as the highly variable immunodominant regions that surround the RBS. HA2 and the N-and C-terminal regions of HA1 form the highly conserved, membrane-proximal stem. HA1 interacts first with sialylated receptors on the host-cell epithelial surface, after which the bound virus is internalized by endocytosis. At the low pH of endosomes, the fusion potential of HA is activated, and HA dramatically rearranges to release its fusion peptide, which anchors to the endosomal membrane, thereby triggering events that lead to fusion of the viral and host membranes (7 ) .
Recent breakthroughs in isolation and characterization of human broadly neutralizing antibodies (bnAbs) [reviewed in (8, 9) ] against HA have raised hopes for a more universal vaccine, as well as the possibility of designing therapeutics that target this region and may be less prone to resistance. Such bnAbs target the HA membraneproximal stem region and block the large conformational rearrangements associated with membrane fusion, thereby neutralizing the virus. Structural characterization of their epitopes identified a highly conserved site of vulnerability at the HA1/ HA2 interface in the HA stem that is present on influenza A group 1 and group 2 serotypes-which encompass 18 HA subtypes (H1 to H18)-and on both influenza B lineages (10) .
This relatively recent structural information from bnAb-HA complexes has already inspired and guided the design of nonimmunoglobulin protein scaffolds against the HA stem (11, 12) . Small proteins, such as HB80 and HB36, were engineered de novo on the basis of the paratope of bnAb CR6261 and its interactions with the HA stem. Particular amino acid side chains were designed to occupy conserved hydrophobic pockets in the HA stem and then displayed in the appropriate configuration and conformation on selected scaffold proteins. These small proteins show comparable affinity, mode of binding, and neutralization breadth to CR6261, and they inhibit the low-pH conformational change in HA. Improved variants of HB36 also protect mice against lethal challenge from the 2009 H1N1 pandemic virus (13) .
The success of these effective protein scaffolds encouraged us to explore the feasibility of engineering even smaller ligands against influenza virus. Smaller peptidic ligands present a promising alternative to biologics by retaining high affinity and selectivity and overcoming challenges such as cell permeability, low bioavailability, and high production cost (14) . Furthermore, passive immunotherapy against influenza currently requires hospitalization for intravenous treatment (15) . Strategies to develop peptides based on complementaritydetermining region (CDR) loops have been reported for other viral targets (16) (17) (18) . However, the absence of any structural insights into their mechanism of action has hindered further development. Our approach was guided by the collective structural information derived from the interactions of several hydrophobic pockets in the influenza HA stem with heavy-chain CDR (HCDR) loops and framework region 3 (FR3) of bnAbs FI6v3 and CR9114. Here we report on the successful development and structural characterization of potent cyclic peptides as influenza HA fusion inhibitors.
bnAb-guided peptide design
A rich compendium of structural and functional information is available on HA stem-targeting bnAbs encoded by germline genes V H 1-69 [CR9114 (10), CR6261 (19) , F10 (20) , and A06 (21)] and V H 3-30 [FI6v3 (22), 3.1 (23) , and 39.29 (24) ]. BnAbs CR6261, F10, A06, and 3.1 are specific against influenza A group 1 viruses, whereas FI6v3, 39.29, and CR9114 show pan-influenza reactivity against influenza A group 1 and 2, and CR9114 also shows reactivity against influenza B viruses. All of these bnAbs interact with a highly conserved hydrophobic groove at the HA1/HA2 interface in the HA stem. For CR9114, the key interacting residues are derived from HCDR2, HCDR3, and FR3, whereas in FI6v3, HCDR3 serves as the dominant interacting motif (Fig. 1A) . Therefore, to recapitulate most of these interactions within a single peptide with greater feasibility of cyclization, the HCDR3 loop of FI6v3 was chosen as the starting point for construction of peptidic ligands (Fig. 1, B and C) .
A series of linear peptides varying in length, terminal-capping moieties, and mutations (table  S1 and 
In vitro affinity maturation of stem-targeting peptides
Starting from the sequence of P1, the peptide conformation was constrained by cyclization. To determine optimal ring size, a library of cyclic peptides of varying lengths was constructed, incorporating nonproteinogenic amino acids (NPAAs) for lactam formation and using various cyclization strategies (head to tail, side chain to side chain, and side chain to tail). In the side chain to tail constructs, an ornithine (Orn In the next round, further optimization was aided by our cocrystal structure of P2 with H1 HA from A/Puerto Rico/8/1934 (H1N1) (H1/PR8) ( ) (Fig. 2C and fig. S3 ). Peptides P4, P5, and P6 (Fig. 1D) were then constructed on the basis of P2 and P3, which suggested that rigidification of the peptide macrocycle and optimization of the HA-peptide interactions through incorporation of NPAAs could improve stability of the complex and enhance binding and neutralization. All three peptides demonstrated improved binding (K D ), complex stability (k off ), and potency (IC 50 ) compared with P3 (Fig. 2, A and C) . Whereas P4 showed modest improvement of two-to threefold (K D = 47 to 75 nM; IC 50 = 76 to 228 nM), P5 and P6 exhibited three to 13 times the affinity and potency (K D = 17 to 37 nM; IC 50 = 30 to 70 nM) against all three HAs tested (Fig. 2 , A and C, and figs. S2 and S3). Furthermore, these peptides neutralized H1N1 and H5N1 viruses (Fig. 2B) .
To investigate whether binding and neutralization could be further improved, the enhancing features of P4, P5, and P6 were incorporated into a single peptide, P7 (Fig. 1D) . P7 showed similar affinity, potency, and virus neutralization to P5 and P6 (Fig. 2 , A to C, and figs. S2 and S3), but the HA-P7 complex was more stable, with k off lower by a factor of 2 to 25 (0.01 to 0.03 s ) and a halflife (t 1/2 ) 2 to 12 times as long (27 to 48 s) (Fig. 2C) . Further, P7 demonstrated broad group 1 specificity when tested against a panel of HAs from the influenza A (groups 1 and 2) and B viruses (figs. S4 and S5 and table S3).
2 of 7 Structural analysis of cyclic peptide binding to HA Crystal structures of cyclic peptides (P2 to P7) in complex with H1/PR8 HA were determined at resolutions of 2.28 to 3.10 Å (Figs. 2 to 4 , figs. S6 to S9, and tables S4 and S5). All peptides recognize the highly conserved hydrophobic stem groove (Fig. 2, D and E, and fig. S6 ). The peptides contact HA1 residues 18, 38 to 42, and 318, the HA2 A-helix (residues 38 to 56), and a turn encompassing HA2 residues 19 to 21 (Fig. 2D) . These residues are similar to the epitopes of the stemtargeting bnAbs (CR9114, FI6v3, CR6261, and F10) (Fig. 3, A and B) .
The nonpolar contacts made by the hydrophobic residues in the peptide macrocycles can be grouped into two distinct regions on the HA stem (Fig. 2D) , and Tyr 5 (Fig. 2, D and E; peptide residue abbreviations are in Fig. 1D) (Fig. 2, D and E) . Polar interactions include 11 hydrogen bonds; six are direct and five are mediated through water molecules (Fig. 2F) ) rigidifies the peptide backbone in P4 and also mediates entropy gain by displacing a conserved water molecule bound to the A-helix (Fig. 3, C and E , respectively (Fig. 3, C and F) . Such interactions in halogen-aromatic systems can contribute binding energies of up to~2.0 kcal/mol (25) . In P6, XE 11 rigidifies the peptide macrocycle by forming an intramolecular hydrogen bond with Glu 4 (Fig. 3 , C and G).
Group 1 HA binding specificity
Despite the presence of interacting residues from pan-influenza antibodies FI6v3 and CR9114, and despite targeting the same epitope on the surface of HA, the peptides neutralized group 1 and not group 2 or influenza B viruses (Fig. 2B) . This activity can be rationalized by comparing the structures of apo and bnAb-complexed HAs from groups 1 and 2 with the peptide-HA complexes determined in this study. The key differences between the peptide epitope on H1 HAs and the corresponding region on H3 HAs are the orientation of HA2 (10, 22) .
Comparison of peptide P6 and FI6v3 bound to group 1 H1 HA shows a perfect overlay of Phe 6 and Phe 100D (Fig. 4 , A and C), whereas when FI6v3 is bound to group 2 H3 HA, Phe 100D is displaced outwardly by~1 Å relative to Phe 6 (Fig. 4, B H3 HA Trp 21 (Fig. 4D) . Similarly, steric clashes between the corresponding Phe of group 1-specific antibodies (CR6261 and F10) and Trp 21 of group 2 HA probably contribute to their group 1 specificity.
The second difference pertains to a glycosylation site at HA1 Asn 38 in group 2 HAs. In unliganded (apo) group 2 HAs, the Asn 38 glycan projects toward the HA2 A-helix of the same HA subunit so that it would overlap with the expected footprint of the stem-targeting antibodies and the peptides. Notwithstanding this, when bnAbs FI6v3 and CR9114 bind group 2 HAs, they are able to reorient the glycan to insert their heavychain CDRs into the corresponding hydrophobic groove and acquire cross-group reactivity. The peptides do not appear to be capable of reorienting the glycan and, therefore, would experience steric clashes of XA 1 , Leu 3 , and Tyr 5 with the Asn 38 glycan on group 2 HAs (Fig. 4F) .
The third key difference arises at position 49 in the A-helix, where the bulkier Asn 49 in H3 HAs would clash with the ornithine (Orn 2 ) introduced into the peptides for cyclization (Fig. 4G) . Overall, the crystal structures indicate that the cumulative effects of these differences account for why the peptides do not interact with group 2 HAs.
Mechanism of viral fusion inhibition
Viral fusion with the host cell membrane is mediated by a large conformational change in HA that is triggered by the low pH of the endosome. Stem-targeting bnAbs, such as CR9114, FI6v3, and CR6261, inhibit viral fusion by stabilizing the trimer even at low pH (10, 19, 22) . Because the peptides mimic the binding modes of these antibodies, we expected that they would have a similar mechanism of action. The first piece of evidence came from crystallization of the P3, P4, P5, and P7 peptide-HA complexes under low-pH conditions (pH 4.0 to 5.0), well below the pH of membrane fusion (table S4) (7) . The H1/ PR8 HA structure in complex with various peptides is essentially identical to that of the prefusion apo HA ( fig. S9) . Therefore, the peptides appear to stabilize the prefusion state of HA and prevent the pH-dependent conformational rearrangements that lead to membrane fusion (Fig. 5A) .
To directly assess inhibition of the HA rearrangements that are associated with fusion activation by the peptides, we performed conformational change inhibition (CCI) and trypsin susceptibility (TS) assays (19, 27) (Fig. 5, B to D; figs. S10 and S11; and table S6). All of the cyclic peptides prevented the conformational change at low pH in the CCI assay (table S6) , and the CCI-derived IC 50 and virus neutralization assayderived median effective concentration (EC 50 ) values correlated well with kinetic parameters derived from SPR (Fig. 5, C to E, and supplementary text S3). The TS assay with representative peptide P7 corroborated the CCI assay results. Therefore, the reported peptides are not only strong HA binders, but also effective inhibitors of the low-pH conformational change. These data imply that, like the bnAbs, the cyclic peptides function by stabilizing the HA trimer throughout endosomal entry and subsequent trafficking to late endosomes (28) .
In vitro stability and in vivo pharmacokinetic profiling of a peptide
To investigate the translational potential of the cyclic peptides identified in this study, we performed in vitro stability and in vivo pharmacokinetic analyses (Fig. 6) . In vitro stability of peptide P7 was assessed in human and mouse plasma. P7 (~2 mg/ml) was incubated with the plasma at 37°C and measured by LC-MS/MS. P7 did not show degradation over the entire time course (~4 hours; Fig. 6A ), implying that cyclization and incorporation of NPAAs endow the peptide with resistance to proteolytic cleavage. In vivo pharmacokinetic profiling was then used to assess the stability and clearance of P7 after intravenous administration in BALB/c mice. P7 has a t 1/2 of~2.7 hours and was cleared from plasma in~24 hours (Fig. 6B) .
Furthermore, the peptides did not show any cytotoxic effects in the human lung-derived Calu-3 cell line ( fig. S12) . These translational data demonstrate that the peptidic fusion inhibitors discovered in this work are highly promising for the development of influenza therapeutics.
Implications for therapeutics against influenza virus
Here we report on the development of effective peptidic inhibitors of influenza virus that neutralize by inhibiting the HA conformational rearrangements at low pH. Extensive data from virus neutralization assays, AlphaLISA assays, SPR, TS assays, CCI assays, x-ray crystallography, and in vitro and in vivo stability studies, as well as their lack of cytotoxicity, provide validation that these peptide fusion inhibitors have potential to translate into the clinic. The peptides were designed on the basis of how the antigen-binding loops of pan-influenza A (and B) antibodies interact with diverse HAs. Constraining the peptide macrocycle by cyclization and addition of nonproteinogenic amino acids led to improvement in the affinity and potency of peptides P4, P5, P6, and P7. Structural characterization illustrated that the peptides recognize the highly conserved HA stem epitope and explained their specificity for influenza A group 1 viruses. Thus, the peptides developed in this work should accelerate the field of small-molecule therapeutics against influenza HA (27) . This approach could be further applied to other sites of vulnerability on the HA and to other pathogenic viruses such as HIV-1, Ebola, and Zika.
6 of 7 The trypsin susceptibility assay establishes that peptide P7 inhibits the low pH-induced conformational changes in H1/PR8 HA. Exposure to low pH renders the H1/PR8 HA sensitive to trypsin digestion (lanes 7 versus 8), but P7 prevents its conversion to a trypsin-susceptible conformation (lanes 11 versus 12). The mechanism is similar to that of fusion inhibiting CR9114 Fab (lanes 9 versus 10). (C to E) Correlation of IC 50 with SPR-derived constants K D and t 1/2 , and of EC 50 with t 1/2 , were derived from conformational change inhibition (CCI) and virus neutralization assays. R 2 , coefficient of determination. 
